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Abstract 250 words 
Introduction: Prostaglandins are important inflammatory mediators; PGE2 is the 
predominant prostaglandin in colorectal neoplasia and affects colorectal carcinogenesis. 
Prostaglandins are metabolites of omega-6 and omega-3 polyunsaturated fatty acids; their 
biosynthesis is the primary target of nonsteroidal anti-inflammatory drugs (NSAIDs), which 
reduce colorectal neoplasia risk.  
Methods: We investigated candidate and tagSNPs in PGE2 synthase (PGES), PGE2 
receptors (EP2 and EP4), and prostaglandin dehydrogenase (PGDH) in a case-control study of 
adenomas (n=483) vs. polyp-free controls (n=582) and examined interactions with NSAID use 
or fish intake, a source of omega-3 fatty acids.  
Results: A 30% adenoma risk reduction was observed for EP2 4950G>A (intron 1; 
ORGA/AA vs. GG: 0.71; 95% CI: 0.52-0.99). For the candidate polymorphism EP4 Val294Ile, 
increasing fish intake was associated with increased adenoma risk among those with variant 
genotypes, but not among those with the Val/Val genotype, (p-interaction=0.02). An interaction 
with fish intake was also observed for PGES -664A>T (5’UTR; p-interaction=0.01). Decreased 
risk with increasing fish intake was only seen among those with the AT or TT genotypes (OR>2 
t/wk vs. <1 t/wk: 0.56; 95% CI: 0.28-1.13). We also detected interactions between NSAIDs and EP2 
9814C>A (intron 1) and PGDH 343C>A (intron 1). However, none of the observed associations 
was statistically significant after adjustment for multiple testing. We investigated potential gene-
gene interactions using the Chatterjee 1df Tukey test and logic regression; neither method 
detected significant interactions. 
Conclusions: These data provide little support for associations between adenoma risk and 
genetic variability related to PGE2, yet suggest gene-environment interactions with anti-inflammatory 
exposures. 
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Introduction 
 Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are effective 
chemopreventive agents for colorectal adenomas and cancer (1-4). The main targets of NSAIDs 
are the COX-1 and COX-2 proteins, which catalyze the first step in the prostaglandin synthesis 
pathway. This pathway metabolizes omega-6 (n-6) and n-3 poly-unsaturated fatty acids into 
prostaglandins, many of which are potent inflammatory mediators. Prostaglandin E2 (PGE2), one 
of the main downstream products of COX metabolism, is upregulated in colon cancer(5) and is 
associated with increased cell proliferation, survival, and motility (6-8). Apc Min mice treated with 
PGE2 have increased intestinal tumor number and size, compared to untreated mice (9). 
Conversely, PGE2 receptor knockout mice show reduced intestinal tumorigenesis (10-12). 
 PGE2 is produced by prostaglandin E2 synthase, of which there are three forms (13). One 
of these, microsomal prostaglandin E2 synthase-1 (PGES), is induced by pro-inflammatory 
stimuli and is preferentially coupled to COX-2 over COX-1 in several tissues (14). PGES is 
overexpressed in colorectal adenomas and cancer (13, 15), and transfection of PGES in concert 
with COX-2 resulted in faster growth, increased cell aggregation, and abnormal cell morphology 
(16), indicating that induction of PGES may be driving prostaglandin-related inflammatory 
processes. 
PGE2 signals through four G-protein-coupled cell-surface receptors, referred to as EP1-4. 
The four receptor types have different downstream mechanisms of signal transduction, resulting in a 
wide variety of functions, although EP2 and EP4 have similar modes of action (17). Of the four EP 
receptors, EP2 and EP4 have been the most consistently linked to colorectal carcinogenesis (10, 
12, 17, 18). APCΔ716/EP2-receptor-null mice had fewer intestinal polyps, reduced tumor growth, and 
reduced angiogenesis (10, 11, 19), indicating that PGE2 signaling through this receptor is an 
important contributor to colorectal neoplasia. Higher EP2 expression was associated with poorer 
colorectal cancer survival in a study of 99 Swedish cancer patients (18).  
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In mouse models, knocking out EP4, either through genetic deletion or through treatment 
with an EP4-receptor antagonist reduced the formation of aberrant crypt foci and decreased polyp 
formation (12). In an in vitro study, treatment of cells with an EP4 agonist countered the 
chemopreventive effects of NSAID treatment (20), indicating that PGE2 signaling through the EP4 
receptor also plays an important role in the development of colorectal neoplasia. However, in mouse 
models of colitis, a condition predisposing to colorectal cancer, treatment with EP4 agonists 
ameliorates symptoms (21, 22), indicating that the full extent of the relationship between EP4 and 
colon carcinogenesis is not yet well understood.  
Prostaglandins can be inactivated by 15-hydroxyprostaglandin dehydrogenase (PGDH) 
(23). APC Min -/- mice exhibit lower PGDH expression than APC Min +/- mice, and Pgdh knock-
out mice have greatly increased tumor development (24, 25). Human colon cancer cell lines 
exhibit low levels of PGDH expression compared to normal colon mucosa (24, 26), and 
expression of PGDH mRNA in human colon cancer tissues is greatly reduced compared to 
normal colon tissue (24-26). PGDH expression is also reduced in inflammatory bowel disease 
(27), a condition associated with markedly increased colorectal cancer risk.  
 Use of NSAIDs substantially reduces PGE2 levels (28-30), induces PGDH expression 
(24, 31, 32), and may decrease expression of EP2 (33), indicating that reduction of PGE2 
production or signaling may be important mechanisms by which NSAIDs prevent colorectal 
neoplasia. Dietary factors also can influence prostaglandin levels. n-3 PUFAs, such as 
eicosapentaenoic acid, compete with arachidonic acid for metabolism by the prostaglandin 
pathway, resulting in production of 3-series prostaglandins that have reduced inflammatory 
potential (34-36). Thus, higher intakes of n-3 fatty acids, which are abundant in fatty fish, may 
also result in reduced risk of colorectal adenoma or cancer. 
 Given the known relevance of this pathway to colorectal carcinogenesis, we evaluated 
genetic variability in key proteins related to PGE2 synthesis, inactivation, and signaling in 
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relation to colorectal polyp risk. We have previously shown that genetic variability in the 
prostaglandin synthesis pathway may alter the chemopreventive associations between 
adenoma risk and NSAID use or fish intake (a proxy for n-3 polyunsaturated fatty acid intake) 
(37-40). We and others have screened the coding regions of PGES, EP2, and EP4 for 
polymorphisms (41, 42). We investigated potential associations between tagSNPs in PGES, 
EP2, EP4, and PGDH, as well as two rare candidate non-synonymous SNPs (nsSNPs) in EP4, 
and risk of colorectal adenoma. We further explored potential interactions between these 
polymorphisms and use of aspirin or other NSAIDs and fish intake.  
 
Materials and Methods 
Study Population. Participant recruitment has been previously described (4, 43, 44). 
Briefly, adenoma cases and colonoscopy-screened polyp-free controls were recruited through a 
large multiclinic gastroenterological practice in the Twin cities area of Minnesota from April 
1991-April 1994. Eligibility criteria have been described elsewhere (43), participants recruited 
prior to colonoscopy and were aged 30-74 years, English-speaking residents of the Twin Cities 
metropolitan area with no known genetic syndrome associated with increased risk of colon 
neoplasia and no individual history of cancer (except non-melanoma skin cancer), prior 
colorectal polyps, or inflammatory bowel disease. The participation rate for all patients who 
underwent colonoscopy was 68%.  
Information on use of aspirin or other NSAIDs, diet, physical activity, anthropometrics, 
demographics, and medical history was obtained via questionnaire. Participants reported the 
average weekly consumption of aspirin and other NSAIDs, and the duration of use. Study 
participants were provided with a list of 14 common aspirin brands and 24 common non-aspirin 
NSAIDs. Non-NSAIDs, that were to be excluded from responses (e.g., acetaminophen), were also 
listed for guidance. 
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Information about regular weekly fish intake over the year prior to polyp diagnosis or 
reference date was obtained using a food frequency questionnaire (FFQ). The FFQ was an 
adaptation of the Willett semiquantitative FFQ, which has been studied previously for validity and 
repeatability within the Nurses’ Health Study cohort (45), the Iowa Women’s Health Study cohort 
(46), and the Health Professionals Follow-up Study cohort (47). Participants were asked four 
questions regarding their usual intakes of various types of fish, including canned tuna, fatty fish, 
and white fish. These responses were combined to form a total fish intake variable.  
Candidate SNP selection. Polymorphisms that may affect protein levels or function are 
referred to as candidate polymorphisms. In our recent screening of PGES, EP2, and EP4 (41), 
only two non-synonymous polymorphisms in EP4, Thr176Ile (MAF 1%) and Val294Ile (MAF 
3%), were found in Caucasians. Of these, Thr176Ile was predicted to affect protein function 
using the SIFT and PolyPhen algorithms (41). We genotyped both of these nsSNPs in the 
present study.  
TagSNP selection. The coding regions, as well as 2KB 5’ and 3’ of PGES, EP2, EP4, 
and PGDH, were resequenced in 23 individuals of European descent and 24 individuals of 
African-American descent by the University of Washington-Fred Hutchinson Cancer Research 
Center Variation Discovery Resource (42). TagSNPs were selected from the European-descent 
population using the LD Select algorithm developed by Carlson and colleagues (48), with a 
cutoff minor allele frequency (MAF) of 4% (i.e., any variant that occurred twice among the 
European population) and an r2 value of 0.90. This resulted in the selection of 10 tagSNPs in 
PGES, 11 in EP2, 11 in EP4, and 32 in PGDH, estimated by the Genome Variation Server (49) 
to cover 85% of the common (≥4% MAF) variation in these loci (see Supplemental Table S1). A 
total of 51 SNPs successfully converted to the Illumina™ GoldenGate genotyping platform. Most 
of the polymorphisms that failed to convert (10/13) were “singleton” SNPs, not tagging for any 
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other polymorphisms; the three failed SNPs that tagged “bins” of LD, as well as two candidate 
polymorphisms, were subsequently genotyped individually at FHCRC (see below). 
Genotyping. The majority (51/56) of SNPs were genotyped using the Illumina™ 
GoldenGate bead-based genotyping technology at the Translational Genomics Institute (TGen, 
Phoenix, AZ). For polymorphisms that were not amenable to high-throughput methods, 
genotyping was conducted at FHCRC. These polymorphisms (EP4 Thr176Ile, EP4 Val294Ile, 
PGES -1254T>C, PGDH 12184A/-, and PGDH 19979A>T) were detected by allelic 
discrimination using the 5’ nuclease assay on a 7900HT sequence detection system (Applied 
Biosystems, Foster City, CA). The 5’ nuclease genotyping assays were validated by genotyping 
92 individuals by both 5’ nuclease assay and RFLP. There were no discrepancies between the 
two assays. The 5 μl genotyping reactions contained Taqman universal master mix, primers, 
probes, and 2 ng of genomic DNA. Positive controls for all the genotypes as well as two 
negative controls were included on each plate. 
 Genotype Quality Control. Intraplate and interplate replicates at a rate of 5% were 
included on all plates and in all batches. Blinded duplicates were also included on all plates as 
another quality control measure. Genotype data from 30 CEPH trios (Coriell Cell Repository, 
Camden, NJ) genotyped by the HapMap project were used to confirm reliability and 
reproducibility of the genotyping. Genotypes were excluded from analyses if SNPs had <85% 
call rate, <85% concordance with blinded or non-blinded duplicates, or Hardy-Weinberg 
Equilibrium p<0.0001 (see Supplemental Table S1). Eight tagSNPs were excluded due to 
quality control errors; leaving a total of 46 tagSNPs and two candidate SNPs in four genes 
included in the analyses presented here.  
Statistical Analysis.  
Single SNP Analyses: Unconditional, logistic regression was used to estimate the odds 
ratio (OR) and corresponding 95% confidence interval (CI) for the associations between 
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genotypes in PGES, EP2, EP4, and PGDH and risk of adenoma. Most SNPs were analyzed 
using indicator variables for the heterozygous and homozygous variant genotype groups (co-
dominant or unrestricted model). If fewer than ten cases or controls had the homozygous variant 
genotype, we grouped the homozygous variant genotypes with the heterozygous genotypes for 
analysis (dominant model). In main-association models of genotypes, associations were 
adjusted for age and sex. Effect modification by NSAID use or fish intake was evaluated in two 
ways: 1) by the inclusion of multiplicative interaction terms in logistic regression models; and 2) 
by testing for a difference in trends within strata of genotype or NSAID/fish, coded as a 
continuous variable. Because use of NSAIDs or dietary intakes of fish may be associated with 
other known risk factors for colorectal neoplasia, we adjusted our NSAID- and fish-gene 
interaction analyses for age, sex, body mass index, dietary intakes of fiber, alcohol, and energy, 
postmenopausal hormone use, and smoking. Because of possible racial differences in genotype 
frequencies, our analyses were restricted to Caucasian individuals (97% of the total study 
population). To obtain tests for trend, the genotypes were treated as a continuous variable, with 
the wildtype genotypes coded as 0, the heterozygous as 1, and the homozygous variant as 2. 
All statistical analyses were carried out using SAS v.9. As a secondary analysis, p-
values were adjusted for multiple testing taking into account correlated tagSNPs using the 
p(ACT) method (50). We corrected for multiple testing on the gene level, i.e. all tests within a 
gene were corrected for the total number of SNPs within a gene. 
Whole gene analyses: Haplotype analysis and principal components analysis (PCA) 
were used to evaluate the combined association of tagSNPs on a gene level (i.e. all SNPs in a 
gene were analyzed together). Haplotypes blocks were determined in Haploview (51) using the 
Gabriel method (52); the resulting blocks were individually analyzed in R v.2.8.0 using a 
modified version of the haplo.stats package (53), which allows adjustment for age and sex. All 
haplotypes with more than 5% frequency in the controls were included in the logistic regression 
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models as a categorical variable; haplotypes with less than 5% frequency were grouped and 
included in the model as one variable. The most common haplotype among the controls was 
used as the referent group. Gene-level significance was determined using a score test of the 
haplotypes included in the model. 
For PCA (54), we determined the number of principal components that explained at least 
80% of the variance in adenoma risk and performed logistic regression using those major 
components, adjusted for age and sex. The gene-level significance was determined using a 
likelihood ratio test comparing a model that contained the principal components and one that did 
not. 
Gene-gene interactions: We evaluated gene-gene interactions using two methods: 1) the 
Tukey 1df interaction test proposed by Chatterjee et al (55) and 2) logic regression (56). For the 
Chatterjee method, we performed the test of interaction in two ways: 1) by deriving scores for 
each parameter and then testing the maximum score against the normal distribution (i.e. 
asymptote-based testing); or 2) by permutation-testing. Logic regression is a model selection 
method that uses Boolean logic to find combinations of variables that predict the outcome 
variable (56). For the purposes of these comparisons, we ran models of various sizes to 
compare the fit and we also have performed Monte Carlo logic regression (57) to obtain a list of 
SNPs that show up frequently in the best fitting model, suggesting that these SNPs might be 




Characteristics of the study population have been described previously (4, 43, 58) and 
are shown for the genotyped subset in Table 1 (n= 483 adenoma cases and 582 polyp-free 
controls. Briefly, the study population was mostly Caucasian (97%); adenoma cases tended to 
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be older than controls and more likely to be male. Regular aspirin or other NSAID use was 
somewhat more common among controls than among adenoma cases (aspirin: OR 0.63, 95% 
CI 0.44-0.90; other NSAIDs: OR 0.50, 95% CI 0.31-0.82) (4). The quality control results for each 
SNP are shown in Supplemental Table S1. 
Main SNP associations. Associations between risk of adenoma and tagSNPs in PGES, 
EP2, EP4, and PGDH are shown in Tables 2 and 3. We observed a marginally significant 
association with EP2 4950G>A (ORGA or AA vs. GG: 0.71; 95% CI: 0.52-0.99). There were no 
individuals with the variant genotype in the candidate SNP EP4 Thr176Ile in the study 
population, so data for that polymorphism are not shown. There was no association with the 
candidate SNP EP4 Val294Ile (Table 2). The heterozygous genotype for EP4 -1307G>A was 
associated with a 40% increase in adenoma risk compared to the most common genotype 
(ORGA vs. GG: 1.42; 95% CI: 1.06-1.91). An increase in risk was also observed for the 
homozygous variant genotype group; however, this was not statistically significant (Table 2). 
For PGDH, we observed two associations of marginal statistical significance (Table 3). 
The heterozygous genotype of 782A>G was associated with decreased adenoma risk 
compared to wildtype (ORAG vs. AA: 0.76; 95% CI: 0.57-1.01) although the homozygous variant 
genotype was not associated with polyp risk. Similarly, the heterozygous genotype of 1543G>A 
was associated with a decreased risk of marginal statistical significance, compared to wildtype 
(ORGA vs. GG: 0.78; 95% CI: 0.58-1.07), whereas the homozygous variant genotype was not 
associated with altered risk. No associations were observed for tagSNPs in PGES. 
Fish interactions. We observed several interactions between fish intake and tagSNPs 
in PGES, EP4, and PGDH. In PGES, a statistically significant interaction with fish intake was 
observed for PGES -664A>T (Table 4 and Figure 1). Fish intake was not associated with 
adenoma risk among those with the wildtype genotype (OR1-2/wk v. <1/wk: 0.93; 95% CI 0.65-1.34: 
OR >2/wk v. <1/wk: 1.31; 95% CI: 0.83-2.04); however, among those with the variant genotypes, 
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higher fish intake was associated with decreased adenoma risk (OR>2/wk v. <1/wk: 0.56; 95% CI: 
0.28-1.13; p-trend interaction=0.01).  
For the candidate polymorphisms EP4 Val294Ile, among the Val/Val genotype group, 
increasing fish intake was associated with a possibly decreased risk of adenoma (OR>2/wk v. <1/wk: 
0.87; 95% CI: 0.58-1.31), whereas among those with at least one Ile allele, higher fish intake 
was associated with substantially increased adenoma risk (p-trend interaction=0.01; Table 4). 
However, the EP4 Val294Ile is a rare polymorphism and the numbers of subjects with a variant 
allele were very small (n= 44), indicating that this interaction requires confirmation in a larger 
population.  
For PGDH 31659T>C (3’ UTR), no association with fish intake was observed among 
those with the common genotype. Those with the heterozygous or homozygous variant 
genotypes had a reduced adenoma risk with increasing weekly fish intake (p-trend 
interaction=0.02; Table 4). No interactions with fish intake were observed for EP2. None of the 
observed interactions remained statistically significant when adjusted for multiple comparisons. 
NSAID interactions. We also evaluated NSAID interactions, but we observed no strong 
interactions. For two SNPs (EP2 9814C>A [intron 1] and PGDH 343C>A [intron 1]), there were 
marginal or statistically significant interactions (see Supplemental Table S2). We analyzed 
NSAID interactions using the wildtype non-NSAID users as the referent group. For the EP2 
SNP, the risk reduction associated with regular NSAID use was more pronounced among those 
with at least one of the more common alleles. However, for PGDH 343C>A among NSAID non-
users, the variant genotypes were associated with increased risk (ORCA or AA vs. CC: 1.98; 95% CI: 
1.18-3.33); among regular NSAID users, decreased adenoma risk was observed for all 
genotypes (p-interaction=0.03). No interactions with NSAID use were observed for SNPs in 
PGES or EP4. None of the interactions remained statistically significant when adjusted for 
multiple comparisons. 
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Gene-level analyses. Haplotype and PCA analysis results are shown in Supplemental 
Tables S3 and S4, respectively. There were no statistically significant associations observed for 
any of the four genes.  
 Gene-gene interaction analyses. The results of Chatterjee gene-gene interaction 
testing are shown in Supplemental Table S5. No statistically significant gene-gene interactions 
were detected. The results of logic regression modeling are shown in Supplemental Tables S6-
S8. In Supplemental Table S6, the variables that were included in models of various sizes are 
shown. The most commonly occurring pairs of SNPs in 100,000 iterations of Monte Carlo Logic 
Regression are shown in Supplemental Table S7. None of the pairs of SNPs occur with ≥1% 
frequency in 100,000 iterations, indicating that important SNP-SNP interactions are unlikely in 
these genes. The most commonly occurring SNPs are shown in Supplemental Table S8. The 
most commonly occurring single SNPs in 100,000 iterations of Monte Carlo Logic Regression 
were EP4 -1307G>A, which occurred with a frequency of 13.3% and EP2 4950G>A, which 
occurred with a frequency of 7.3%; these were the only SNPs that occurred with a frequency 
greater than 5%. Our finding that no single SNP was selected for inclusion in more than 15% of 
fitted models indicates that none of the SNPs we genotyped in these four genes is strongly 
related to risk of adenoma. This reflects the main SNP association findings, in which we 
detected very few statistically significant main associations. 
  
Discussion 
 We investigated genetic variability in a biochemical pathway that has been unequivocally 
linked to colorectal carcinogenesis and has not yet been previously studied in the context of 
colorectal adenoma. Our results indicate that genetic variability related to PGE2 signaling is 
generally not related to risk of colorectal adenoma. However, some data from this study suggest 
that genetic variability in PGES, EP2, EP4, or PGDH may alter the anti-inflammatory effects of 
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specific fatty acids or NSAID use. We hypothesized that NSAID use or high fish intake would be 
associated with lower risk of colorectal neoplasia, predominantly among those with genetic 
variants that are likely to increase PGE2 production or signaling. We observed a statistically 
significant association for a tagSNP in EP2 and in EP4, but no other associations between 
tagSNPs in PGES or PGDH and risk of colorectal adenomas. Further, we observed several 
statistically significant or marginally significant interactions with NSAID use or fish intake, 
indicating that the consequences of genetic variability in prostaglandin synthesis may be further 
modified by underlying dietary or pharmacologic pro- or anti-inflammatory profiles. For the 
tagSNPs that were associated with adenoma risk or interacted with inflammatory exposures, we 
investigated their LD with any potentially functional SNPs (Supplemental Table S9) by 
evaluating SNP locations, regulatory regions, and conservation across species. However no 
SNPs with clear functional significance were identified. 
 
 To our knowledge, no previous studies have examined associations between genetic 
variants in PGES, EP2, EP4, and PGDH and risk of adenoma. However, although our findings 
require confirmation in additional studies, our results suggest similar patterns to previous reports 
on interactions between polymorphisms in COX-1, COX-2, and PGIS, in which the inverse 
associations with NSAID use or fish intake were limited to certain genotype groups (37-40). Two 
EP2 tagSNPs included in this study, -616G>C and -166G>A, were associated with aspirin-
intolerant asthma in Korean individuals (59). Although that study was small and 77 
polymorphisms were tested without correction for multiple testing, those results indicate that 
polymorphisms in EP2 may be a predictor of who is likely to benefit from (or even experience 
adverse reactions from) aspirin. Two EP2 SNPs included in the present study (-1722A>G and -
616G>C) were not associated with hypertension in a study of 266 Japanese subjects (60) and 
also were not associated with adenoma risk in the present study. In a recent whole genome 
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association study of Crohn’s disease, an inflammatory bowel condition, SNPs upstream of EP4 
linked to altered EP4 expression were associated with increased risk (61). However, these 
SNPs were not included in the present study because they are over 200KB upstream of EP4. In 
a study of lymphoma risk, three polymorphisms in PGES that were not included in this study 
(but one of which was tagged in our study by another SNP), were not associated with risk of 
lymphoma (62).  
 This study has several limitations. First, a large number of statistical tests were 
performed, increasing the likelihood of false positives. Although we corrected for multiple 
testing, we chose to report the uncorrected p-values. However, given both the importance of 
PGE2 for colorectal carcinogenesis and the fact that no one has yet reported on potential 
associations with tagSNPs in these genes for colorectal neoplasia risk, we decided to report all 
our findings for possible replication by other groups. Conversely, due to the relatively small 
number of study subjects, it is possible that true associations or gene-environment interactions 
were missed.  
 Intakes of specific types of fish were not measured in this study. Because fish vary in 
their content of n-3 polyunsaturated fatty acids, total fish intake is not a precise measure of n-3 
polyunsaturated fatty acid intake. Further, we did not have a quantitative measure of dietary n-6 
polyunsaturated fatty acids nor of fish oil or other fatty acid-containing supplements. This limited 
our power to detect true interactions between dietary fatty acids and genetic variability related to 
PGE2 signaling on risk of colorectal adenoma. 
 This study has several strengths. First, all controls who participated in this study 
underwent colonoscopy prior to enrollment. Because colorectal polyps are common in older 
adults, an unscreened population-based control group would include undiagnosed adenoma 
cases, resulting in disease misclassification and an attenuation of any true associations. In 
addition, by using tagSNPs as well as rare non-synonymous SNPs to investigate associations 
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between these target genes and risk of colorectal adenoma, we achieved comprehensive 
coverage of these genes, increasing the likelihood of observing any existing true association. 
The prostaglandin synthesis pathway is an important one for colorectal carcinogenesis and our 
complete coverage of the genes and their 5’ and 3’ regions, as well as some lifestyle factors that 
are likely to influence prostaglandin synthesis, provides a more complete investigation of this 
pathway. 
 In summary, the results from the present study provide some limited evidence that 
genetic variability in genes related to PGE2 levels and signaling may be modifiers of the 
relationship between NSAID use or fish intake and risk of colorectal adenoma.  
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Table 1. Characteristics of the study populationa 
  Adenomas Controls p-value 
  N=483 N=582  
  Mean (SD) Mean (SD)  
Age (years) 58.0 (9.6) 52.9 (11.0) <0.0001 
Caloric Intake (kcal/day) 2110.2 (766.9) 2019.2 (708.9) 0.05 
Alcohol Intake (gm/day) 10.5 (17.0) 6.6 (13.4) <0.0001 
Dietary Fiber Intake (gm/day) 21.9 (9.5) 21.7 (9.6) 0.79 
   
  N (%) N (%)  
Location of largest adenoma   
  Proximal 102 (21.3) NA  
  Distal 298 (62.2) NA  
  Rectal 79 (16.5) NA NA 
Sex    
  Male 304 (62.9) 229 (39.4)  
  Female 179 (37.1) 353 (60.6) <0.0001 
Regular Use of Aspirin or NSAIDs   
  Yes 174 (36.0) 258 (44.3)  
  No 309 (64.0) 324 (55.7) 0.006 
Smoking (pack-years)    
  0 164 (34.7) 278 (49.0)  
  1-25 148 (31.3) 172 (30.3)  
  >25 161 (34.0) 117 (20.6) <0.0001 
BMI    
  Normal/Underweight 157 (33.2) 227 (39.9)  
  Overweight (25-29.9) 202 (42.7) 214 (37.6)  
  Obese (30+) 114 (24.1) 128 (22.5) 0.08 
Fish intake (servings/week)    
  <1 111 (23.2) 123 (21.8)  
  1-2 237 (49.6) 298 (52.7)  
  >2 130 (27.2) 144 (25.5) 0.60 
Post-menopausal Hormone Useb   
  No 103 (58.2) 161 (45.6)  
  Yes 70 (39.6) 181 (51.3)  
 Not sure 4 (2.3) 11 (3.1) 0.02 
a Numbers may not total to 1.00 due to rounding and missing values 
b Females only 
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Table 2. Genetic variation in PGES, EP2, and EP4 and risk of colorectal adenomaa 
Gene SNP Genotypeb Cases Controls OR 95%CI pc p-trend
PGES -1254T>C TT 435 526 1.00 —   
  TC or CC 40 40 1.28 0.79-2.07 0.32 NA 
        
 -664A>T AA 397 468 1.00 —   
  AT or TT 86 114 0.94 0.67-1.30 0.69 NA 
        
 211A>G AA 313 381 1.00 —   
  AG 147 175 1.10 0.83-1.45   
  GG 22 21 1.23 0.64-2.36 0.70 0.40 
        
 1152G>A GG 429 510 1.00 —   
  GA or AA 54 72 0.92 0.62-1.36 0.66 NA 
        
 3006G>A GG 459 546 1.00 —   
  GA or AA 24 36 0.86 0.49-1.51 0.60 NA 
        
 13425A>C AA 435 526 1.00 —   
  AC or CC 40 40 1.28 0.79-2.07 0.40 NA 
        
EP2 -1722A>G AA 171 222 1.00 —   
  AG 234 269 1.22 0.92-1.62   
  GG 78 89 1.20 0.81-1.77 0.35 0.23 
        
 -967G>A GG 436 531 1.00 —   
  GA or AA 47 51 1.14 0.74-1.78 0.55 NA 
        
 -616G>C GG 367 444 1.00 —   
  GC or CC 116 137 1.01 0.75-1.36 0.96 NA 
        
 1690G>A GG 448 539 1.00 —   
  GA or AA 34 43 1.05 0.64-1.73 0.83 NA 
        
 4950G>A GG 400 448 1.00 —   
  GA or AA 83 134 0.71 0.52-0.99 0.04 NA 
        
 9814C>A CC 288 349 1.00 —   
  CA 159 197 1.00 0.76-1.32   
  AA 36 35 1.10 0.66-1.85 0.93 0.80 
        
 12010G>A GG 342 406 1.00 —   
  AG 122 157 0.96 0.72-1.29   
  AA 19 19 1.03 0.52-2.05 0.96 0.89 
        
 15674G>A GG 311 384 1.00 —   
  AG 145 177 1.01 0.76-1.33   
  AA 27 21 1.41 0.76-2.62 0.55 0.48 
        
EP4 Val294Ile Val/Val 476 565 1.00 —   
  Val/Ile 20 25 0.93 0.49-1.75 0.82 NA 
        
 -1529G>A GG 186 238 1.00 —   
  GA 218 263 0.91 0.69-1.20   
  AA 79 79 0.81 0.55-1.19 0.54 0.27 
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 -1408G>A GG 251 326 1.00 —   
  GA 199 223 0.87 0.66-1.13   
  AA 32 31 0.84 0.49-1.45 0.53 0.28 
        
 -1307G>A GG 169 166 1.00 —   
  GA 211 293 1.42 1.06-1.91   
  AA 103 123 1.19 0.83-1.70 0.06 0.23 
        
 -132C>G CC 401 475 1.00 —   
  CG or GG 82 106 0.89 0.64-1.24 0.49 NA 
        
 1455A>G AA 175 225 1.00 —   
  AG 203 254 0.90 0.68-1.20   
  GG 86 88 0.81 0.56-1.19 0.54 0.27 
        
 2472A>G AA 137 182 1.00 —   
  AG 222 280 0.92 0.68-1.25   
  GG 122 120 0.74 0.52-1.06 0.23 0.11 
        
 6374G>A GG 278 351 1.00 —   
  GA 181 199 0.86 0.66-1.13   
  AA 24 32 1.13 0.63-2.03 0.46 0.63 
        
 8907G>A GG 219 278 1.00 —   
  GA 206 240 0.90 0.69-1.18   
  AA 58 64 0.89 0.58-1.36 0.71 0.45 
        
 11851G>A GG 379 454 1.00 —   
  GA or AA 103 128 1.06 0.78-1.45 0.71 NA 
        
 13877A>C AA 257 315 1.00 —   
  AC 196 223 0.90 0.69-1.18   
  CC 29 43 1.22 0.72-2.06 0.49 1.00 
        
 13981A>G AA 178 195 1.00 —   
  AG 220 289 1.27 0.95-1.68   
  GG 85 98 1.05 0.72-1.53 0.23 0.50 
a Adjusted for age and sex. 
b The homozygous variant and heterozygous genotypes are grouped together if <10 cases or 
<10 controls were of the homozygous variant genotype. 
c Likelihood ratio test of a model containing dummy variables for each SNP + age and sex vs. a 
model containing only age and sex. 
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Table 3. Genetic variation in PGDH and risk of colorectal adenomaa 
SNP Genotypeb Cases Controls OR 95%CI pc p-trend 
-1868G>A GG 359 437 1.00 —   
 GA or AA 124 145 1.10 0.82-1.48 0.51 NA 
       
-1635G>A GG 121 164 1.00 —   
 GA 238 288 1.22 0.89-1.66   
 AA 122 128 1.31 0.91-1.88 0.30 0.14 
       
343C>A CC 412 511 1.00 —   
 CA or AA 70 71 1.31 0.90-1.91 0.16 NA 
       
Gln52Gln GG 171 192 1.00 —   
 GA 225 283 0.97 0.73-1.29   
 AA 84 104 1.00 0.68-1.45 0.98 0.94 
       
782A>G AA 338 384 1.00 —   
 AG 129 187 0.76 0.57-1.01   
 GG 15 10 1.51 0.64-3.56 0.09 0.29 
       
1113G>A GG 374 464 1.00 —   
 GA or AA 109 118 1.14 0.84-1.56 0.41 NA 
       
1543G>A GG 137 155 1.00 —   
 GA 214 287 0.78 0.58-1.07   
 AA 131 139 0.95 0.67-1.35 0.24 0.73 
       
3580G>A GG 297 337 1.00 —   
 GA 161 220 0.84 0.64-1.10   
 AA 25 25 1.15 0.62-.13 0.37 0.53 
       
9442A>G AA 223 298 1.00 —   
 AG 210 217 1.21 0.92-1.58   
 GG 50 66 0.95 0.62-1.46 0.32 0.63 
       
9691C>A CC 247 286 1.00 —   
 CA 187 249 0.89 0.68-1.17   
 AA 48 47 1.29 0.81-2.05 0.28 0.77 
       
12184A/- AA 375 427 1.00 —   
 A/- or -/- 110 136 0.94 0.69-1.28 0.70 NA 
       
13316A>C AA 221 255 1.00 —   
 AC 208 259 0.95 0.72-1.24   
 CC 53 68 0.94 0.61-1.44 0.91 0.69 
       
13796C>T CC 273 322 1.00 —   
 CT 177 217 0.99 0.76-1.30   
 TT 33 43 0.90 0.54-1.50 0.92 0.77 
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16362G>A GG 282 363 1.00 —   
 GA 168 182 1.16 0.88-1.53   
 AA 33 36 1.06 0.63-1.78 0.57 0.43 
       
17450A>G AA 394 445 1.00 —   
 AG or GG 88 135 0.79 0.58-1.09 0.15 NA 
       
18349G>A GG 379 452 1.00 —   
 GA or AA 104 129 0.96 0.71-1.31 0.81 NA 
       
19433G>A GG 243 275 1.00 —   
 GA 201 259 0.91 0.70-1.19   
 AA 37 48 0.88 0.54-1.44 0.76 0.47 
       
19979A>T AA 338 378 1.00 —   
 AT 135 166 0.96 0.72-1.28   
 TT 14 19 0.86 0.40-1.84 0.90 0.67 
       
20518A>G AA 160 208 1.00 —   
 AG 228 267 1.08 0.81-1.44   
 GG 95 107 1.12 0.78-1.62 0.79 0.50 
       
23196G>A AA 262 304 1.00 —   
 AG 180 243 0.87 0.67-1.14   
 GG 41 33 1.39 0.83-2.34 0.19 0.82 
       
26646G>A GG 320 381 1.00 —   
 GA 141 175 0.98 0.74-1.30   
 AA 22 26 1.09 0.58-2.06 0.95 0.94 
       
31659A>G AA 356 420 1.00 —   
 AG 111 144 0.90 0.67-1.22   
 GG 14 18 0.92 0.43-1.97 0.79 0.52 
a Adjusted for age and sex. 
b The homozygous variant and heterozygous genotypes are grouped together if <10 cases or <10 
controls were of the homozygous variant genotype. 
c Likelihood ratio test of a model containing dummy variables for each SNP + age and sex vs. a model 
containing only age and sex. 
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Table 4. Genetic variation in PGES, EP4, and PGDH, weekly fish intake, and risk of adenomaa 
 Fish intake 
 <1 serving per week 1-2 servings per week >2 servings per week
Gene SNP Cases Controls OR 95% CI Cases Controls OR 95% CI Cases Controls OR 95% CI
PGES -664A>T             
  AA 90 106 1.00 — 190 239 1.06 0.72-1.55 113 108 1.31 0.83-2.04 
  AT or TT 21 17 1.74 0.81-3.76 47 59 1.01 0.59-1.71 17 36 0.56 0.28-1.13 
   global p-interaction=0.02
   SNP trendb p-interaction=0.01
                
EP4 Val294Ile             
 Val/Val 110 116 1.00 — 235 288 0.90 0.63-1.27 126 45 0.87 0.58-1.31 
 Val/Ile or Ile/Ile 2 8 0.27 0.05-1.41 10 15 0.80 0.32-2.00 8 1 7.75 0.81-78.83
  global p-interaction=0.02
  SNP trendb p-interaction=0.01
            
PGDH 19979A>T           
 AA 78 83 1.00 — 156 196 0.95 0.63-1.45 99 90 1.26 0.78-2.05 
 AT or TT 30 38 1.06 0.56-2.00 86 87 1.25 0.78-2.03 33 53 0.64 0.35-1.18 
  global p-interaction=0.03 
  SNP trendb p-interaction=0.03 
            
 31659A>G           
 AA 76 99 1.00 — 171 209* 1.15 0.77-1.71 105 99 1.35 0.85-2.15 
 AG or GG 34 24 1.86 0.96-3.61 65 89 1.04 0.64-1.70 25 45 0.75 0.40-1.44 
  global p-interaction=0.03
   SNP trendb p-interaction=0.02
a Adjusted for age, BMI, total intakes of energy, alcohol, and fiber, sex, post-menopausal hormone use (women only), and smoking (pack-years) 
b Test for differences in fish intake trend among strata of genotype 
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Figure 1 caption. PGES -664T>A, weekly fish intake, and risk of adenoma. 
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